DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug repurposed to fight rare scleroderma in early trial
Disease control CompletedThis early-phase study tested a drug called brentuximab vedotin, originally used for lymphoma, in 17 people with a severe form of scleroderma (diffuse cutaneous systemic sclerosis). The main goal was to see if the drug is safe and tolerable. Researchers monitored for serious side…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug shows promise for rare scleroderma in phase 2 trial
Disease control CompletedThis study tested an experimental drug called MT-7117 in 76 adults with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. Participants received either the drug or a placebo for 52 weeks. The main goal was to see if MT-71…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC